Table 5.

Cases that meet the release criteria based on the cumulative dose evaluation for each patient

Radionuclides for medical use	Scope of application	Dose (MBq)
Iodine (131I)	Residual thyroid ablation after total thyroidectomy in differentiated thyroid cancer without distant metastasisa	1110
Radium (223Ra)	Treatment of castration-resistant prostate cancer with bone metastasisb	12.1c

^a Limited to implementation in accordance with the guidelines prepared by related academic societies (“Outpatient treatment with I-131 (1,110MBq) for the purpose of residual thyroid destruction”).

^b Limited when it is performed by administering 55 kBq/kg per dose of radium chloride (Ra-223) injection at 4-week intervals (up to 6 times) according to the implementation guidelines prepared by related academic societies (“Proper use manual for internal therapy using radium chloride (Ra-223) injection”).

^c Maximum dose